Document:

Exhibit
10.5

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of October 30, 2018, between Ritter
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory
hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

 

This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser
(the “Purchase Agreement”).

 

The
Company and each Purchaser hereby agrees as follows:

 

1.
Definitions.

 

Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms
in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Advice”
shall have the meaning set forth in Section 6(d).

 

“Effectiveness
Date” means, with respect to the Initial Registration Statement required to be filed hereunder, the 60th
calendar day following the date hereof (or, in the event of a “full review” by the Commission, the 90th
calendar day following the date hereof) and with respect to any additional Registration Statements which may be required pursuant
to Section 2(c) or Section 3(c), the 60th calendar day following the date on which the Company first knows, or reasonably
should have known, that an additional Registration Statement is required to be filed hereunder (or, in the event of a “full
review” by the Commission, the 90th calendar day following the date such additional Registration Statement is
required to be filed hereunder); provided, however, that in the event the Company is notified by the Commission
that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments,
the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company
is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on
a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Event”
shall have the meaning set forth in Section 2(d).

 

“Event
Date” shall have the meaning set forth in Section 2(d).

 

    	 

    	 

    

 

“Filing
Date” means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day
following the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section
2(c) or Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration
Statement related to the Registrable Securities.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Plan
of Distribution” shall have the meaning set forth in Section 2(a).

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A or Rule 430B
promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect
to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments
and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to
be incorporated by reference in such Prospectus.

 

“Registrable
Securities” means, as of any date of determination, (a) all of the shares of Common Stock then issued and issuable upon
conversion in full of the Series B Preferred Stock (assuming on such date the shares of Series B Preferred Stock are converted
in full without regard to any limitations on conversion set forth in the Series B Certificate of Designation), (b) all of the
shares of Common Stock then issued and issuable upon conversion in full of the Series C Preferred Stock (assuming on such date
the shares of Series C Preferred Stock are converted in full without regard to any limitations on conversion set forth in the
Series C Certificate of Designation), (c) all Warrant Shares then issued and issuable upon exercise of the Warrants (assuming
on such date the Warrants are exercised in full without regard to any exercise limitations therein), and (d) any securities issued
or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;
provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall
not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto)
for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the
Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such
effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c)
such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information
pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer
Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange
of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the
Company, and all Warrants are exercised by “cashless exercise” as provided in Section 2(c) of each of the Warrants),
as reasonably determined by the Company, upon the advice of counsel to the Company.

 

    	2

    	 

    

 

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional
registration statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and
supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto,
and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“SEC
Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.

 

“Selling
Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).

 

    	3

    	 

    

 

2.
Registration.

 

(a)
On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the
resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering
to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except
if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration
shall be on another appropriate form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (except
as otherwise directed by at least 85% in interest of the Holders) the “Plan of Distribution” in substantially
the form attached hereto as Annex A (which may be modified to respond to comments, if any, provided by the Commission).
Subject to the terms of this Agreement, the Company shall use its commercially reasonable efforts to cause a Registration Statement
filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act
as promptly as reasonably practicable after the filing thereof, but in any event no later than the applicable Effectiveness Date,
and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities
Act until the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant
to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement
for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel
to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected
Holders (the “Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration
Statement as of 5:00 p.m. Eastern Time on a Trading Day. The Company shall immediately notify the Holders via facsimile or by
e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness
with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by
9:30 a.m. Eastern Time on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with
the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness
or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d).

 

(b)
Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the
Registrable Securities cannot, as a result of the application of Rule 415 or any other basis, be registered for resale as a secondary
offering on a single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially
reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum
number of Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register
for resale the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e); with respect to filing
on Form S-3 or other appropriate form, and subject to the provisions of Section 2(d) with respect to the payment of liquidated
damages; provided, however, that prior to filing such amendment, the Company shall be obligated to use diligent
efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance,
including without limitation, Compliance and Disclosure Interpretation 612.09.

 

    	4

    	 

    

 

(c)
Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d),
if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered
on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to
advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed
in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration
Statement will be reduced as follows:

 

	 	a.	First,
    the Company shall reduce or eliminate any securities to be included other than Registrable Securities;
	 	 	 
	 	b.	Second,
    the Company shall reduce Registrable Securities represented by Series C Conversion Shares into which Exchanged Series C Preferred
    Shares are convertible or have been converted (applied, in the case that some of such Series C Conversion Shares may be registered,
    to the Holders on a pro rata basis based on the total number of unregistered Series C Conversion Shares into which Exchanged
    Series C Preferred Shares are convertible or have been converted held by such Holders);
	 	 	 
	 	c.	Second,
    the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares
    may be registered, to the Holders on a pro rata basis based on the total number of unregistered Warrant Shares held by such
    Holders); and 
	 	 	 
	 	d.	Third,
    the Company shall reduce Registrable Securities represented by Series B Conversion Shares into which Purchased Series B Preferred
    Shares are convertible or have been converted (applied, in the case that some of such Series B Conversion Shares may be registered,
    to the Holders on a pro rata basis based on the total number of unregistered Series B Conversion Shares into which Purchased
    Series B Preferred Shares are convertible or have been converted held by such Holders. 

 

In
the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along
with the calculations as to such Holder’s allotment. In the event the Company amends the Initial Registration Statement
in accordance with the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly
as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration
statements on Form S-3 or such other form available to register for resale those Registrable Securities that were not registered
for resale on the Initial Registration Statement, as amended.

 

    	5

    	 

    

 

(d)
If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration
Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein,
the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request
for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities
Act, within five Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission
that such Registration Statement will not be “reviewed” or will not be subject to further review, or (iii) prior to
the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing
to comments made by the Commission in respect of such Registration Statement within fifteen (15) calendar days after the receipt
of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared
effective, or (iv) a Registration Statement registering for resale all of the Registrable Securities is not declared effective
by the Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration
Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities
included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell
such Registrable Securities, for more than fifteen (15) consecutive Trading Days or more than an aggregate of twenty-five (25)
Trading Days in the aggregate (which need not be consecutive Trading Days) during any 12-month period (any such failure or breach
being referred to as an “Event”, and for purposes of clauses (i) and (iv), the date on which such Event occurs,
and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii)
the date which such fifteen (15) calendar day period is exceeded, and for purpose of clause (v) the date on which such fifteen
(15) or twenty-five (25) Trading Day period, as applicable, is exceeded being referred to as “Event Date”),
then, in addition to any other rights the Holders may have hereunder or under applicable law, (A) within five (5) Trading Days
after an Event Date relating to a failure of clause (i) only and (B) on each monthly anniversary of any such Event Date (if the
applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder
an amount in cash, as partial liquidated damages and not as a penalty, equal to 1.5% of the aggregate Subscription Amount paid
by such Holder pursuant to the Purchase Agreement for any unregistered Registrable Securities then held by such Holder on the
applicable Event Date; provided, however, in the event that at least 50% of the Registrable Securities are registered
on or before the Effectiveness Date, then any partial liquidated damages attributable to any Registrable Shares not registered
as of the Effectiveness Date as a result of the application of Rule 415 shall not begin to accrue until the 180th calendar
date following the Closing Date (and shall only begin to accrue if a Registration Statement registering the remaining Registrable
Securities shall not have been filed and declared effective by the Commission by such date). The parties agree that the maximum
aggregate liquidated damages payable to a Holder under this Agreement shall be 8% of the aggregate Subscription Amount paid by
such Holder pursuant to the Purchase Agreement. If the Company fails to pay any partial liquidated damages pursuant to this Section
in full within seven days after the date payable, the Company will pay interest thereon at a rate of 15% per annum (or such lesser
maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated
damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant
to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.

 

    	6

    	 

    

 

(e)
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register
the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities
on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration
Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been
declared effective by the Commission.

 

3.
Registration Procedures.

 

In
connection with the Company’s registration obligations hereunder, the Company shall:

 

(a)
Not less than three (3) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day
prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated
or deemed to be incorporated therein by reference, but not including (i) any Exchange Act filing or (ii) any supplement or post-effective
amendment to a registration statement that is not related to such Holder’s Registrable Securities), the Company shall (i)
furnish to each Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed
to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause its officers and directors, counsel
and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of
respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. Notwithstanding
the above, the Company shall not be obligated to provide the Holders advance copies of any universal shelf registration statement
registering securities in addition to those required hereunder, or any Prospectus prepared thereto. The Company shall not file
a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of
the Registrable Securities shall reasonably object in good faith, provided that, the Company is notified of such objection in
writing no later than three (3) Trading Days after the Holders have been so furnished copies of a Registration Statement or one
(1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto.
Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex B
(a “Selling Stockholder Questionnaire”) on a date that is not less than two (2) Trading Days prior to the Filing
Date or by the end of the fourth (4th) Trading Day following the date on which such Holder receives draft materials
in accordance with this Section.

 

    	7

    	 

    

 

(b)
(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and
the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective (subject
to any requirement that a post-effective amendment be declared effective by the Commission) as to the applicable Registrable Securities
for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register
for resale under the Securities Act all of the Registrable Securities, subject to any SEC Guidance that sets forth a limitation
on the number of Registrable Securities permitted to be registered on a particular Registration Statement, (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and,
as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments
received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably
possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement
(provided that, the Company shall excise any information contained therein which would constitute material non-public information
as to any Holder which has not executed a confidentiality agreement with respect thereto with the Company regarding the Company
or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and
the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the
applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders
thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.

 

(c)
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common
Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case
prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than
the number of such Registrable Securities.

 

    	8

    	 

    

 

(d)
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be
accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as
reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested
by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus
or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed (but not including
(i) any Exchange Act filing or (ii) any supplement or post-effective amendment to a registration statement that is not related
to such Holder’s Registrable Securities), (B) when the Commission notifies the Company whether there will be a “review”
of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect
to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission
or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or
for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any
stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation
of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of
the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation
or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial
statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement
or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or
that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration
Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect
to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best
interest of the Company to allow continued availability of a Registration Statement or Prospectus, provided, however,
in no event shall any such notice contain any information which would constitute material, non-public information regarding the
Company or any of its Subsidiaries.

 

(e)
Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping
or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification)
of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

    	9

    	 

    

 

(f)
Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto,
including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to
the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished
or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that any such item which
is available on the EDGAR system (or successor thereto) need not be furnished in physical form.

 

(g)
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement
thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such
Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).

 

(h)
Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification)
of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within
the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition
in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided, that, the Company shall
not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company
to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in
any such jurisdiction.

 

(i)
If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free,
to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be
in such denominations and registered in such names as any such Holder may request.

 

    	10

    	 

    

 

(j)
Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking
into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the
premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration
Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference,
and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies
the Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the
requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use
its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The
Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement
and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period
not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.

 

(k)
use its commercially reasonable efforts to comply in all material respects with all applicable rules and regulations of the Commission
in connection with obtaining and maintaining the effectiveness of any Registration Statement required to be filed and maintained
with the Commission hereunder.

 

(l)
The Company shall use its commercially reasonable efforts to maintain eligibility for use of Form S-3 (or any successor form thereto)
for the registration of the resale of Registrable Securities.

 

(m)
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common
Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive
control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration
of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Company’s
request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise
occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.

 

4.
Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company
shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees
and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including,
without limitation, fees and expenses of the Company’s counsel and independent registered public accountants) (A) with respect
to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common
Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to
by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with
Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses
of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements
of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and
expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by
this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the
consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its
officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred
in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall
the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction
Documents, any legal fees or other costs of the Holders.

 

    	11

    	 

    

 

5.
Indemnification.

 

(a)
Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold
harmless each Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable
Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors
and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack
of such title or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents
and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack
of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and
against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees)
and expenses (collectively, “Losses”), as incurred, arising out of or relating to (1) any untrue or alleged
untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any
amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission
of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or
supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation
by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection
with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue
statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder
expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method
of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use
in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has
approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section
3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified
such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to
the receipt by such Holder of the Advice contemplated in Section 6(d), but only if and to the extent that following the receipt
of the Advice the misstatement or omission giving rise to such Loss would have been corrected. The Company shall notify the Holders
promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated
by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders
in accordance with Section 6(h).

  

(b)
Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its
directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the
fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely
upon: (x) such Holder’s failure to comply with any applicable prospectus delivery requirements of the Securities Act through
no fault of the Company or (y) any untrue or alleged untrue statement of a material fact contained in any Registration Statement,
any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any
omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in
the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i)
to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in
writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the
extent, but only to the extent, that such information relates to such Holder’s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it
being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or
supplement thereto or (iii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), to the extent,
but only to the extent, related to the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after
the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by
such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(d), but only if and to the extent
that following the receipt of the Advice the misstatement or omission giving rise to such Loss would have been corrected. In no
event shall the liability of any selling Holder under this Section 5(b) be greater in amount than the dollar amount of the net
proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

    	12

    	 

    

 

(c)
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume
the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all
fees and expenses incurred in connection with defense thereof; provided, that, the failure of any Indemnified Party to give such
notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only)
to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to
appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.

 

An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if
the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party
notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more
than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any
settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed.
No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending
Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such
Indemnified Party from all liability on claims that are the subject matter of such Proceeding.

 

    	13

    	 

    

 

Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses
to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with
this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying
Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and
expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction
(which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.

 

(d)
Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient
to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable
by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified
Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among
other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission
or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by
such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if
the indemnification provided for in this Section was available to such party in accordance with its terms.

 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by
pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to
contribute pursuant to this Section 5(d), in the aggregate, any amount in excess of the amount by which the net proceeds actually
received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages
that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission.

 

    	14

    	 

    
 

The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties.

 

6.
Miscellaneous.

 

(a)
Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under
this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each
of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by
reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action
for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would
be adequate.

 

(b)
No Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except as set forth on Schedule
6(b) attached hereto, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant
hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company
shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement
that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing supplements
or amendments to registration statements filed prior to the date of this Agreement or from filing any registration statements
on Form S-8 or any registration statement with respect to the securities that may be sold to Aspire Capital Fund, LLC pursuant
to the Aspire ELOC Agreement, subject to the restrictions applicable to issuances and sales of Common Stock pursuant to the Aspire
ELOC Agreement set forth in Section 4.12 of the Purchase Agreement.

 

(c)
Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities
Act, if and to the extent applicable to it in connection with sales of Registrable Securities pursuant to a Registration Statement,
unless an exemption therefrom is available to such Holder.

 

(d)
Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice
from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith
discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”)
by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company
will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.
The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the
Registrable Securities hereunder shall be subject to the provisions of Section 2(d).

 

    	15

    	 

    

 

(e)
Piggy-Back Registrations. If, at any time during the Effectiveness Period, there is not an effective Registration Statement
covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration
statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities,
other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity
securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection
with the Company’s stock option or other employee benefit plans or any registration statement with respect to the securities
that may be sold to Aspire Capital Fund, LLC pursuant to the Aspire ELOC Agreement, subject to the restrictions applicable to
issuances and sales of Common Stock pursuant to the Aspire ELOC Agreement set forth in Section 4.12 of the Purchase Agreement,
then the Company shall deliver to each Holder a written notice of such determination and, if within fifteen days after the date
of the delivery of such notice, any such Holder shall so request in writing, the Company shall include in such registration statement
all or any part of such Registrable Securities such Holder requests to be registered; provided, however, that the
Company shall not be required to register any Registrable Securities pursuant to this Section 6(e) that are eligible for resale
pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Commission pursuant
to the Securities Act or that are the subject of a then effective Registration Statement that is available for resales or other
dispositions by such Holder.

 

(f)
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and the Holders of a majority or more of the then outstanding Registrable Securities (for
purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security). If
a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance
with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata
among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from
such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect
to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect
the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver
or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(f). No consideration shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration
also is offered to all of the parties to this Agreement.

 

    	16

    	 

    

 

(g)
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be delivered as set forth in the Purchase Agreement.

 

(h)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights
or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities.
Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the
Purchase Agreement.

 

(i)
No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall
the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities,
that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions
hereof. Except as set forth on Schedule 6(i), neither the Company nor any of its Subsidiaries has previously entered into
any agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied
in full.

 

(j)
Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

(k)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall
be determined in accordance with the provisions of the Purchase Agreement.

 

(l)
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.

 

(m)
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

    	17

    	 

    

 

(n)
Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall
not be deemed to limit or affect any of the provisions hereof.

 

(o)
Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not
joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of
the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any
closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership,
an association, a joint venture or any other kind of group or entity, or create a presumption that the Holders are in any way
acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement
or any other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall
not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce
its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other
Holder to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the
obligations of the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was
done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly
understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between
the Company and the Holders collectively and not between and among Holders.

 

********************

 

(Signature
Pages Follow)

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	RITTER
    PHARMACEUTICALS, INC.
	 	 
	 	By:	                              
	 	Name:	Andrew
    J. Ritter
	 	Title:	President
    and Chief Executive Officer

 

[SIGNATURE
PAGE OF HOLDERS FOLLOWS]

 

    	 

    	 

    

 

[SIGNATURE
PAGE OF HOLDERS TO REGISTRATION RIGHTS AGREEMENT]

 

Name
of Holder: __________________________

 

Signature
of Authorized Signatory of Holder: __________________________

 

Name
of Authorized Signatory: _________________________

 

Title
of Authorized Signatory: __________________________

 

[SIGNATURE
PAGES CONTINUE]

 

    	 

    	 

    

 

Annex
A

 

Plan
of Distribution

 

Each
Selling Stockholder (the “Selling Stockholders”) of the securities and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market
or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales
may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:

 

	 	●	ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;
	 	 	 
	 	●	block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the
    block as principal to facilitate the transaction;
	 	 	 
	 	●	purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;
	 	 	 
	 	●	an
    exchange distribution in accordance with the rules of the applicable exchange;
	 	 	 
	 	●	privately
    negotiated transactions;
	 	 	 
	 	●	settlement
    of short sales; 
	 	 	 
	 	●	in
    transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities
    at a stipulated price per security;
	 	 	 
	 	●	through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
	 	 	 
	 	●	a
    combination of any such methods of sale; or
	 	 	 
	 	●	any
    other method permitted pursuant to applicable law.

 

The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act
of 1933, as amended (the “Securities Act”), if available, rather than under this prospectus.

 

Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities,
from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an
agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a
principal transaction a markup or markdown in compliance with FINRA IM-2440.

 

    	 

    	 

    

 

In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of
hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close
out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling
Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one
or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered
by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the securities.

 

The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The
Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.

 

We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling
Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without
the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act
or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under
the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed
brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered
hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the
registration or qualification requirement is available and is complied with.

 

Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined
in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of
purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus
available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser
at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

 

    	2

    	 

    

 

Annex
B

Ritter
Pharmaceuticals

 

Selling
Stockholder Notice and Questionnaire

 

The
undersigned beneficial owner of common stock (the “Registrable Securities”) of Ritter Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), understands that the Company has filed or intends to file with the
Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration
Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities
Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration
Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is available from
the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings
ascribed thereto in the Registration Rights Agreement.

 

Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the
consequences of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The
undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include
the Registrable Securities owned by it in the Registration Statement.

 

    	3

    	 

    

 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

	1.	Name.

 

	 	(a)	Full
    Legal Name of Selling Stockholder
	 	 	 
	 	 	 
	 	 	 
	 	(b)	Full
    Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
	 	 	 
	 	 	 
	 	 	 
	 	(c)	Full
    Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power
    to vote or dispose of the securities covered by this Questionnaire):
	 	 	 
	 	 	 

 

2.
Address for Notices to Selling Stockholder:

 

	_______________________________________________________________________________________________
	_______________________________________________________________________________________________
	_______________________________________________________________________________________________
	Telephone:
    ______________________________________________________________________________________
	Fax:____________________________________________________________________________________________
	Contact
    Person:___________________________________________________________________________________

 

3.
Broker-Dealer Status:

 

	 	(a)	Are
    you a broker-dealer?

 

	 	Yes
    [  ]	No
    [  ]

 

	 	(b)	If
    “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services
    to the Company?

 

	 	Yes
    [  ]	No
    [  ]

 

	 	Note:	If
    “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter
    in the Registration Statement.

 

	 	(c)	Are
    you an affiliate of a broker-dealer?

 

	 	Yes
    [  ]	No
    [  ]

 

	 	(d)	If
    you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course
    of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings,
    directly or indirectly, with any person to distribute the Registrable Securities?

 

	 	Yes
    [  ]	No
    [  ]

 

	 	Note:	If
    “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter
    in the Registration Statement.

 

4.
Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.

 

Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the securities issuable pursuant to the Purchase Agreement.

 

	 	(a)	Type
    and Amount of other securities beneficially owned by the Selling Stockholder:
	 	 	 
	 	 	 
	 	 	 

 

    	4

    	 

    

 

5.
Relationships with the Company:

 

Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the past three years.

 

State
any exceptions here:

 

	 	 
	 	 

 

The
undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that
may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned
shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its
affiliates.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through
5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements
thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation
or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered
either in person or by its duly authorized agent.

 

	Date:
    	 	 	Beneficial
    Owner: 	 

 

	 	By:	 
	 	Name:	 
	 	Title:	 

 

PLEASE
FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:

 

    	5Exhibit
10.6

 

PLACEMENT
AGENCY AGREEMENT

 

October
31, 2018

 

A.G.P./Alliance
Global Partners

590
Madison Avenue

New
York, NY 10022

 

Ladies
and Gentlemen:

 

Introductory.
Ritter Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to (i) issue and sell to certain
purchasers (collectively, the “Purchasers”) up to $6.0 million of (A) the Company’s Series B Convertible
Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), having the rights, preferences
and privileges set forth in the Certificate of Designation of Rights, Preferences and Limitations to be filed by the Company with
the Secretary of State of the State of Delaware, substantially in the form of Exhibit A-1 attached hereto (the “Series
B Certificate of Designation”), which Series B Preferred Stock shall have a stated value of $1,000 per share and shall
be convertible into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”),
as provided in the Series B Certificate of Designation (such shares of Common Stock into which the Series B Preferred Stock is
convertible, collectively, the “Series B Conversion Shares”), and (B) Common Stock purchase warrants, substantially
in the form of Exhibit B attached hereto (collectively, the “Warrants”), which Warrants shall entitle
the Purchasers to purchase, in the aggregate, a number of shares of Common Stock equal to 50% of the maximum number of Series
B Conversion Shares issuable upon conversion in full of all shares of Series B Preferred Stock purchased by the Purchasers (such
shares of Common Stock issuable upon exercise of the Warrants, collectively, the “Warrant Shares”) and shall
be exercisable for a period of five (5) years, and (ii) issue to certain of the Purchasers, in exchange for their shares of the
Company’s outstanding Series A Convertible Preferred Stock, par value $0.001 per share and stated value $1,000 per share
(the “Series A Preferred Stock”), shares of the Company’s Series C Convertible Preferred Stock, par value
$0.001 per share (the “Series C Preferred Stock”), having the rights, preferences and privileges set forth
in the Certificate of Designation of Rights, Preferences and Limitations to be filed by the Company with the Secretary of State
of the State of Delaware, substantially in the form of Exhibit A-2 attached hereto (the “Series C Certificate
of Designation”), which Series C Preferred Stock shall have a stated value of $1,000 per share and shall be convertible
into shares of Common Stock as provided in the Series C Certificate of Designation (such shares of Common Stock into which the
Series C Preferred Stock is convertible, collectively, the “Series C Conversion Shares”). The Series B Preferred
Stock, the Series B Conversion Shares, the Warrants and the Warrant Shares are collectively referred to herein as the “Purchased
Securities”; the Series C Preferred Stock and the Series C Conversion Shares are collectively referred to herein as
the “Exchanged Securities”; and the Purchased Securities and the Exchanged Securities are collectively referred
to herein as the “Securities”.

 

The
Securities will be offered, issued and sold to (or exchanged with, as applicable) the Purchasers in a private placement (the “Placement”)
without being registered under the Securities Act of 1933, as amended, and the rules and regulations of the Securities and Exchange
Commission (the “Commission”) thereunder (collectively, the “Securities Act”), in reliance
upon Section 4(a)(2) (“Section 4(a)(2)”) thereof and/or Rule 506(b) of Regulation D (“Regulation D”)
thereunder. The Company hereby confirms that A.G.P./Alliance Global Partners has agreed to act as Placement Agent (the “Placement
Agent”) in connection with the Placement, subject to the terms, conditions and other provisions of this Agreement.

 

    	 

    	 

    

 

The
Securities are to be issued and sold to (or exchanged with, as applicable) the Purchasers pursuant to a Securities Purchase Agreement,
substantially in the form of Exhibit C hereto (the “Securities Purchase Agreement”), to be entered into
by the Company and each of the Purchasers. Holders of the Securities will be entitled to the benefits of those certain resale
registration rights set forth in a Registration Rights Agreement, substantially in the form of Exhibit D hereto (the “Registration
Rights Agreement”) to be entered into between the Company and each of the Purchasers, pursuant to which the Company
will agree, among other things, to file with the Commission a resale registration statement pursuant to Rule 415 under the Securities
Act (the “Resale Registration Statement”) covering the resale of the Series B Conversion Shares, the Series
C Conversion Shares and the Warrant Shares, and to use its commercially reasonable efforts to cause the Resale Registration Statement
to be declared effective within the time periods specified in the Registration Rights Agreement.

 

This
Agreement, the Series B Certificate of Designation, the Series C Certificate of Designation, the Warrants, the Securities Purchase
Agreement, the Registration Rights Agreement, and the escrow agreement, substantially in the form of Exhibit E hereto,
to be entered into by the Company, the Placement Agent, Corporate Stock Transfer, Inc., as Escrow Manager, and Collegiate Peaks
Bank, as Escrow Agent, in connection with the Placement (the “Escrow Agreement”), are referred to herein collectively
as the “Transaction Documents”, and the transactions contemplated hereby and thereby are referred to herein
collectively as the “Transaction.”

 

The
Company has prepared a management presentation dated October 2018 (the “Management Presentation”) to be used
in connection with the Placement. The information in the Management Presentation is based upon the Company’s public filings,
including reports filed or furnished by the Company under the Securities Exchange Act of 1934, as amended, and the rules and regulations
of the Commission thereunder (collectively, the “Exchange Act”), from and after January 1, 2015 (the “Public
Filings”). The Management Presentation and the Public Filings, shall collectively be hereinafter referred to as the
“Disclosure Package.”

 

The
Company hereby confirms its agreement with the Placement Agent as follows:

 

Section
1. Representations, Warranties and Agreements of the Company and the Placement Agent.

 

A.
Representations, Warranties and Agreements of the Company. In addition to the other representations, warranties and agreements
contained in this Agreement and in Section 3.1 of Article III of the Securities Purchase Agreement, all of which are incorporated
herein by reference and upon which the Placement Agent may rely as a third-party beneficiary thereof, the Company hereby represents,
warrants and agrees with, the Placement Agent as follows:

 

    	2

    	 

    

 

(a)
No Material Misstatement or Omission. As of their respective dates (or, if amended or superseded by a filing prior to the
closing date of the Placement (the “Closing Date”), then as of the date of such filing), each of the Public
Filings by the Company complied in all material respects with the requirements of the Securities Act and the Exchange Act and
the rules and regulations of the SEC promulgated thereunder. None of the Management Presentation or the Public Filings, as of
their respective dates, contains any untrue statement of a material fact or omits to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(b)
Placement Materials. The Company has delivered to the Placement Agent copies of the Management Presentation in such quantities
and at such places as the Placement Agent has reasonably requested or will reasonably request. The Company has not distributed
and will not distribute, prior to the Closing Date, any materials in connection with the Placement other than the Management Presentation,
its Public Filings and drafts or definitive versions of the Transaction Documents and the other agreements, instruments and documents
to be entered into or delivered in connection with the Transaction.

 

(c)
The Transaction Documents. The Company has all necessary power and authority to execute and deliver the Transaction Documents
and to perform and carry out its obligations hereunder and thereunder; each of the Transaction Documents has been duly authorized
by the Company and, when executed and delivered by the Company, will constitute a valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms.

 

(d)
Forward Looking Statements . The statements (including the assumptions described therein) included in the Management Presentation
(i) are and will be within the coverage of Rule 175(b) under the Securities Act to the extent such data constitute forward looking
statements as defined in Rule 175(c) and (ii) were and will be made by the Company with a reasonable basis and reflect the Company’s
good faith estimate of the matters described therein.

 

(e)
Stock Exchange Listing. The Company shall cause the Series B Conversion Shares, the Series C Conversion Shares and the
Warrant Shares to be listed on The Nasdaq Capital Market prior to the effectiveness of the Resale Registration Statement and shall
use its best efforts to maintain the continued listing of such Series B Conversion Shares, the Series C Conversion Shares and
the Warrant Shares.

 

(f)
Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. The Company’s execution,
delivery and performance of this Agreement, and each of the other Transaction Documents, do not, and will not, (i) conflict with
or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter
documents, (ii) conflict with or violate, or constitute a default (or an event that with notice or lapse of time or both would
become a default) (a “Default”) under or result in the creation or imposition of any security interest, mortgage,
pledge, lien, charge, encumbrance or adverse claim upon any property or assets of the Company, or give to others any rights of
termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, indenture,
mortgage, loan or credit facility, note, contract, franchise, lease, debt or other instrument or other understanding to which
the Company is a party (including, without limitation, any agreement or arrangement between the Company and any other investment
bank, underwriter, placement agent, broker-dealer or finder) or by which any property or asset of the Company is bound, or affected
(each, an “Existing Instrument”) or require the consent of any other party to any Existing Instrument or other
third party, except to the extent that such conflict, default, termination, amendment, acceleration or cancellation right would
not reasonably be expected to have a Material Adverse Change (defined as: any development that could reasonably be expected to
result in a material adverse change in the condition, financial or otherwise, or in the earnings, business, operations or prospects,
whether or not arising from transactions in the ordinary course of business, any such change is called a “Material Adverse
Change”), or (iii) result in a violation of any law, rule, administrative regulation, order, judgment, injunction, administrative
or court decree or other restriction of any court or governmental authority to which the Company is subject, or by which any property
or asset of the Company is bound or affected, except to the extent that such violation would not, individually or in the aggregate,
result in a Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any
court or other governmental or regulatory authority or agency, is required for the Company’s execution, delivery and performance
of this Agreement and the other Transaction Documents other than the Required Approvals (as such term is defined in the Securities
Purchase Agreement).

 

 

    	3

    	 

    

 

(g)
No Price Stabilization or Manipulation; Compliance with Regulation M, etc. The Company has not taken, directly or indirectly,
any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of
its Common Stock or any other “reference security” (as defined in Rule 100 of Regulation M under the 1934 Act (“Regulation
M”)), whether to facilitate the sale or resale of any of the Securities or otherwise, and has taken no action which
would directly or indirectly violate Regulation M or facilitate any short-selling of the Series B Conversion Shares, the Series
C Conversion Shares or the Warrant Shares by Purchasers.

 

(h)
Brokers. Except for the Placement Agent, there is no broker, finder or other party that is entitled to receive from the
Company any brokerage or finder’s fee or other fee or commission as a result of the Placement or the transactions contemplated
thereby.

 

(i)
QIBs and Accredited Investors. The Company will not offer or sell any of the Securities to any person whom it reasonably
believes is not (i) a “qualified institutional buyer” as defined in Rule 144A (“QIBs”) or (ii)
an institutional “accredited investor” (as defined in clauses (1), (2), (3) and (7) of Rule 501(a) of Regulation D).

 

(j)
Purchasers; Compliance With Rule 502(d). The Company will exercise reasonable care to assure that the Purchasers are not
“underwriters” within the meaning of Section 2(a)(11) of the Securities Act and, without limiting the foregoing, that
such purchases will comply with Rule 502(d) under the Securities Act.

 

(k)
No General Solicitation. Neither the Company nor any of its Affiliates have engaged, and will engage, directly or indirectly
in any form of “general solicitation” or “general advertising” in connection with the offering of the
Securities (as those terms are used in Regulation D) under the Securities Act or in any manner involving a public offering within
the meaning of Section 4(a)(2); and the Company has not entered, and will not enter, into any arrangement or agreement with respect
to the distribution of the Securities, except for the Transaction Documents, and the Company agrees not to enter into any such
arrangement or agreement.

 

    	4

    	 

    

 

(l)
No Integration. Neither the Company nor any of its affiliates has directly or indirectly sold, offered for sale, solicited
offers to buy or otherwise negotiated in respect of any “security” (as defined in the Securities Act) that is, or
would be, integrated with the sale of any of the Securities in a manner that would require the registration under the Securities
Act of any of the Securities.

 

(m)
No Transfer Taxes or Other Fees. There are no transfer taxes or other similar fees or charges under United States law or
the laws of any state or any political subdivision thereof, required to be paid in connection with the execution and delivery
of this Agreement and the other Transaction Documents or the issuance and sale by the Company of the Securities.

 

(n)
Patriot Act Compliance. Neither the issuance and sale of the Securities by the Company nor the Company’s use of the
proceeds thereof will violate the Trading with the Enemy Act, as amended, or any of the foreign assets control regulations of
the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order
relating thereto. The Company is in compliance, in all material respects, with the USA Patriot Act of 2001 (signed into law October
26, 2001).

 

(o)
No Offer and Sale Within Six Months. The Company has not sold or issued any security of the same or similar class or series
as any of the Securities or any security convertible into, or exercisable for, shares of Common Stock during the six-month period
preceding the date of the Securities Purchase Agreement, including any sales pursuant to Rule 144A under the Securities Act, Section
4(a)(2) or Regulation D (other than shares issued pursuant to employee benefit plans, qualified stock options plans or other employee
or director compensation plans or pursuant to outstanding options, rights, warrants or other convertible securities), and has
no intention of making, an offer or sale of such securities, for a period of six months after the date of the Securities Purchase
Agreement, except for (i) the offering of Securities as contemplated by the Transaction Documents and (ii) any offer or sale of
securities that would not be integrated with the sale of any of the Securities in a manner that would require the registration
under the Securities Act of the sale by the Company of the Securities, provided that any such offering and sale of securities
(other than shares issued pursuant to employee benefit plans, qualified stock options plans or other employee or director compensation
plans or pursuant to outstanding options, rights, warrants or other convertible securities) made within six months of the date
hereof shall be accompanied by an opinion addressed to or that may be relied upon by the Placement Agent, and provided further,
that in no event shall the Company offer or sell any securities prior to the expiration of the Lock-up Period set forth in Section
4.12(a) of the Securities Purchase Agreement, except as otherwise permitted by Section 4.12 of the Securities Purchase
Agreement. As used in this paragraph, the terms “offer” and “sale” have the meanings specified in Section
2(a)(3) of the Securities Act.

 

    	5

    	 

    

 

(p)
No Disqualification Events. Neither the Company nor any Company Related Persons (as defined below) are subject to any of
the disqualifications set forth in Rule 506(d) of Regulation D (each, a “Disqualification Event”). The Company
has exercised reasonable care to determine whether any Company Related Person is subject to a Disqualification Event. The Disclosure
Package contains a true and complete description of the matters required to be disclosed with respect to the Company and the Company
Related Persons pursuant to the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable. As used herein,
“Company Related Persons” means any predecessor of the Company, any affiliated issuer, any director, executive
officer, other officer of the Company participating in the Placement, any general partner or managing member of the Company, any
beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting
power, and any “promoter” (as defined in Rule 405 under the Securities Act) connected with the Company in any capacity.
The Company will promptly notify the Placement Agent in writing of (1) any Disqualification Event relating to any Company Related
Person and (2) any event that would, with the passage of time, become a Disqualification Event relating to any Company Related
Person.

 

(q)
Certificates. Any certificate signed by an officer of the Company and delivered to the Placement Agent in connection herewith
shall be deemed to be a representation and warranty by the Company to the Placement Agent as to the matters set forth therein.

 

(r)
Disclosure. No representation or warranty contained in Section 2 of this Agreement contains any untrue statement of a material
fact or omits to state a material fact necessary to make the statements herein not misleading in the context of such representations
and warranties.

 

The
Company acknowledges that each of the Placement Agent and, for purposes of the opinion to be delivered pursuant to Section
4 hereof, counsel to the Company, will rely upon the accuracy and truthfulness of the foregoing representations and hereby
consents to such reliance.

 

B.
Representations, Warranties and Agreements of the Placement Agent. The Placement Agent hereby represents, warrants and
covenants to, and agrees with, the Company as follows:

 

(a)
No General Solicitation. The Placement Agent will not solicit offers for the Company for the Securities by means of any
form of general solicitation or general advertising in connection with the offering of the Securities or in any manner involving
a public offering within the meaning of Section 4(a)(2).

 

(b)
Limitation on Offerees. The Placement Agent will solicit offers for the Company for the Securities only from persons whom
it reasonably believes to be (i) a QIB or (ii) an institutional “accredited investor” (as defined in clauses (1),
(2), (3) and (7) of Rule 501(a) of Regulation D).

 

(c)
Authority. This Agreement has been duly authorized, executed and delivered by the Placement Agent, and upon due execution
and delivery by the Company, this Agreement will be a valid and binding agreement of the Placement Agent enforceable against it
in accordance with its terms, except as may be limited by principles of public policy and, as to enforceability, subject to applicable
bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditor’s rights from time
to time in effect and subject to general equity principles.

 

    	6

    	 

    

 

(d)
No Conflict. None of the execution or delivery of or performance by the Placement Agent under this Agreement or any other
agreement or document entered into by the Placement Agent in connection herewith or the consummation of the transactions herein
or therein contemplated conflicts with or violates, any agreement or other instrument to which the Placement Agent is a party
or by which its assets may be bound, or its limited liability company agreement, or any license, permit, judgment, decree, order,
statute, rule or regulation applicable to the Placement Agent or any of its assets, except in each case as would not have a material
adverse effect on the transactions contemplated hereby.

 

(e)
No Disqualification Event. Neither the Placement Agent nor any Placement Agent Related Persons (as defined below) are subject
to any Disqualification Event as of the date hereof. The Placement Agent has exercised reasonable care to determine whether any
Placement Agent Related Person is subject to such a Disqualification Event. As used herein, “Placement Agent Related
Persons” means any predecessor of the Placement Agent, any affiliated issuer, any director, executive officer, other
officer of Placement Agent participating in the Placement, any general partner or managing member of the Placement Agent, any
beneficial owner of 20% or more of the Placement Agent’s outstanding voting equity securities, calculated on the basis of
voting power, and any “promoter” (as defined in Rule 405 under the Securities Act) connected with the Placement Agent
in any capacity. The Placement Agent agrees to promptly notify the Company in writing of (1) any Disqualification Event relating
to any Placement Agent Related Person and (2) any event that would, with the passage of time, become a Disqualification Event
relating to any Placement Agent Related Person.

 

Section
2. Engagement of Placement Agent; Fees; Expenses.

 

(a)
Engagement of Placement Agent. The Company agrees that it has engaged A.G.P./Alliance Global Partners as its exclusive
placement agent with respect to the Placement, and the Company hereby authorizes the Placement Agent as its exclusive placement
agent to act as such in connection with the Placement. On the basis of the representations, warranties and agreements of the Company
contained in or incorporated by reference into this Agreement, and subject to, and in accordance with, the terms, conditions and
other provisions hereof, A.G.P./Alliance Global Partners agrees to act as exclusive Placement Agent to place the Securities as
contemplated by this Agreement and the Securities Purchase Agreement. The term of the Placement Agent’s exclusive engagement
will be until the earlier of (i) November 30, 2018 and (ii) the completion and consummation of the Placement, subject to earlier
termination pursuant to and in accordance with Section 7 below and giving effect to any required notice period as therein
provided (the “Offering Period”). The date on which the Offering Period expires or terminates referenced in
the immediately preceding sentence is referred to herein as the “Termination Date.” The Company acknowledges
that the Placement Agent’s engagement hereunder does not constitute any firm commitment or undertaking, express or implied,
on the part of the Placement Agent to purchase or place any of the Securities and does not constitute any representation, warranty
or agreement that any financing will be available to the Company.

 

(b)
Placement Agent’s Fees and Expenses. As compensation for the Placement Agent’s services hereunder, the Company
hereby agrees to pay the Placement Agent, on the Closing Date, a cash fee in an amount equal to seven percent (7%) of the aggregate
gross proceeds from the sale of the Series B Preferred Stock and Warrants to the Purchasers in the Placement, excluding any proceeds
received from the sale of Securities by the Company to MedPace Inc. In addition to any fees that may be paid to the Placement
Agent hereunder, whether or not any Transaction occurs or the Placement Agent’s engagement and/or this Agreement is otherwise
terminated by any party or expires, the Company shall reimburse the Placement Agent, promptly upon receipt of an invoice therefor,
for all out-of-pocket expenses (including, without limitation, the reasonable fees and expenses of Placement Agent’s counsel,
and the reasonable fees and expenses of any other independent experts retained by the Placement Agent) incurred by the Placement
Agent in connection with the Transactions and the Engagement Letter (defined below), in an amount not to exceed $35,000 in the
aggregate (including the fees and expenses of Placement Agent’s counsel), without the Company’s prior consent (not
to be unreasonably withheld); provided, however, that such expense cap in no way limits or impairs the indemnification and contribution
provisions of this Agreement or the Engagement Letter.

 

    	7

    	 

    

 

(c)
Placement Agent as Independent Contractor. The Company hereby acknowledges that, in connection with the Transactions, (i)
the Placement, including the determination of the offering price of the Preferred Stock and Warrants, the initial conversion price
of the Preferred Stock and the initial exercise price of the Warrants, and any related discounts, commissions and fees, shall
be an arm’s-length commercial transaction between the Company and the Purchasers, (ii) the Placement Agent will be acting
as an independent contractor and will not be the agent or fiduciary of the Company or its stockholders, creditors, employees,
the Purchasers or any other party, (iii) the Placement Agent shall not assume an advisory or fiduciary responsibility in favor
of the Company (irrespective of whether the Placement Agent has advised or is currently advising the Company on other matters)
and the Placement Agent shall not have an obligation to the Company with respect to the Transactions except as may be set forth
expressly herein, (iv) the Placement Agent and its affiliates may be engaged in a broad range of transactions that involve interests
that differ from those of the Company and (v) the Placement Agent shall not provide any legal, accounting, regulatory or tax advice
with respect to the Transactions and the Company shall consult its own legal, accounting, regulatory and tax advisors to the extent
it deems appropriate.

 

(d)
Company Responsible for the Disclosure Package. The Company is and will be solely responsible for the contents of the Disclosure
Package and any and all other written or oral communications provided to any actual or prospective purchaser of the Securities
with the approval of the Company; and the Company recognizes that the Placement Agent, in acting pursuant to this Agreement, will
be using information provided by the Company and its agents and representatives and the Placement Agent does not assume responsibility
for, and may rely, without independent verification, on the accuracy and completeness of any such information.

 

(e)
Notification of Potential Purchasers. In order to allow proper coordination of the proposed Placement, during the term
of this engagement, the Company will promptly notify the Placement Agent of any potential purchasers known to the Company to be
interested in purchasing any of the Securities, and the Company will keep the Placement Agent fully and promptly informed of the
status of any discussions or negotiations between the Company and any such potential purchasers.

 

(f)
Confidentiality. The Company agrees that any information or advice rendered by any Placement Agent or any of its representatives
in connection with this engagement is for the confidential use of the Company only and the Company will not, and will not permit
any third party to, disclose or otherwise refer to such advice or information, or to the Placement Agent, in any manner without
the Placement Agent’s prior written consent.

 

    	8

    	 

    

 

Section
3. Additional Covenants and Agreements of the Company. The Company further covenants and agrees with the Placement Agent as
follows:

 

(a)
Placement Agent’s Review of Proposed Amendments and Supplements. During the period beginning on the date hereof and
ending on the Closing Date, prior to amending or supplementing the Disclosure Package (including any amendment or supplement of
any Public Filing that is incorporated or deemed incorporated by reference therein), the Company shall furnish to the Placement
Agent for review a copy of each such proposed amendment or supplement prior to its distribution or filing.

 

(b)
Amendments and Supplements to the Disclosure Package. If, prior to the Closing Date, any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the information or documents, or other information or documents
incorporated or deemed incorporated by reference, in the Disclosure Package (including any amendment or supplement of any Public
Filing that is incorporated or deemed incorporated by reference therein) in order to make the statements therein, in the light
of the circumstances when the Management Presentation or any other document contained or incorporated or deemed incorporated by
reference in the Disclosure Package is delivered to a Purchaser, not misleading, or if it is otherwise necessary to amend or supplement
any portion of the Disclosure Package to comply with law, the Company agrees to promptly prepare and furnish at its own expense
to the Placement Agent, amendments or supplements to the Disclosure Package so that the statements therein as so amended or supplemented
will not, in the light of the circumstances when the Disclosure Package is delivered to a Purchaser, be misleading or so that
the Disclosure Package, as amended or supplemented, will comply with law. Neither the Placement Agent’s consent to, or delivery
of, any such amendment or supplement shall constitute a waiver of any of the Company’s obligations under this Section
3 (b).

 

(c)
Copies of any Amendments and Supplements to the Disclosure Package. The Company agrees to furnish the Placement Agent and
counsel to the Placement Agent, without charge, as soon as available, as many copies of any amendments and supplements to the
Disclosure Package (including any documents incorporated or deemed incorporated by reference therein) as the Placement Agent or
its counsel may request.

 

(d)
Marketing. The Company shall participate, and cause its officers and representatives to participate, in the Placement as
reasonably requested by the Placement Agent, including meeting and participating in telephonic conferences with prospective purchasers
of any of the Securities, and afford prospective purchasers the opportunity to conduct customary due diligence and make inquiries
relevant to their investment decisions regarding the Securities.

 

(e)
Blue Sky Compliance. The Company shall cooperate with the Placement Agent and counsel for the Placement Agent to qualify
or register the Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws
of those jurisdictions designated by the Placement Agent, shall comply with such laws and shall continue such qualifications,
registrations and exemptions in effect so long as required for the distribution of the Securities. The Company shall not be required
to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction
where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise
the Placement Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the
Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose,
and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use
its best efforts to obtain the withdrawal thereof at the earliest possible moment.

 

    	9

    	 

    

 

(f)
Use of Proceeds. The Company shall apply the net proceeds from the sale of the Securities sold by it in the manner described
in Section 4.7 of the Securities Purchase Agreement and Schedule 4.7 thereto.

 

(g)
Transfer Agent. The Company shall maintain, at its expense, a registrar and transfer agent for the Securities.

 

(h)
Investment Limitation. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale
of the Securities in such a manner as would require the Company to register as an investment company under the Investment Company
Act.

 

(i)
No Stabilization or Manipulation. The Company will not take, directly or indirectly, any action designed to or that might
be reasonably expected to cause or result in stabilization or manipulation of the price of the Common Stock or any other reference
security, whether to facilitate the sale or resale of the Securities or otherwise.

 

(j)
Press Release. The Company will not, prior to the earlier of the Closing Date or the termination of this Agreement, issue
any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its
condition, financial or otherwise, or earnings, business affairs or business prospects (except for routine communications and
presentations in the ordinary course of business and consistent with the past practices of the Company and of which the Placement
Agent and its counsel are notified), without the prior written consent of the Placement Agent, unless in the judgment of the Company
and its counsel, and after notification to the Placement Agent and its counsel, such press release or communication is required
by law.

 

Section
4. Conditions of the Placement Agent’s Obligations. The obligations of the Placement Agent as provided herein shall
be subject to the accuracy of the representations, warranties and agreements of the Company set forth herein as of the date hereof
and as of the Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations
hereunder, and to each of the following conditions:

 

(a)
No Material Adverse Change. For the period from and after the date of this Agreement and prior to the Closing Date, in
the sole and absolute discretion of the Placement Agent, there shall have not occurred any Material Adverse Change.

 

(b)
Opinions of Counsel for the Company. On the Closing Date, the Placement Agent shall have received an opinion letter of
counsel to the Company, dated as of such Closing Date, expressing (i) each of the opinions substantially in the form set forth
on Exhibit F hereto and (ii) each of the opinions expressed in the opinion letter provided to the Purchasers by counsel
to the Company on the Closing Date pursuant to the Securities Purchase Agreement. Alternatively, the opinions set forth on Exhibit
F hereto may be provided in a separate opinion letter of counsel to the Company, dated as of such Closing Date, addressed
and delivered only to the Placement Agent, in which case the opinion letter provided to the Purchasers by counsel to the Company
on the Closing Date pursuant to the Securities Purchase Agreement shall also be addressed and delivered to the Placement Agent.

 

    	10

    	 

    

 

(c)
Officers’ Certificate. On the Closing Date, the Placement Agent shall have received a written certificate executed
by the President and Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated
as of the Closing Date, to the effect that:

 

(i)
for the period from and after the date of this Agreement and prior to the Closing Date, there has not occurred any Material Adverse
Change;

 

(ii)
the representations, warranties and covenants of the Company set forth in Section 1(A) of this Agreement and incorporated
herein by reference from the Securities Purchase Agreement are true and correct with the same force and effect as though expressly
made on and as of such Closing Date; and

 

(iii)
the Company has performed, satisfied and complied with all the covenants, agreements and conditions required hereunder at or prior
to such Closing Date.

 

(d)
No Material Misstatement or Omission. The Placement Agent shall not have discovered and disclosed to the Company prior
to or on the Closing Date that the Disclosure Package, in the opinion of counsel to the Placement Agent, contains an untrue statement
of a material fact or omits to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

 

(e)
Placement Agent’s Fees and Expenses. The Placement Agent’s fees and expense reimbursement described in Section
2(b) of this Agreement shall have been paid to the Placement Agent by wire transfer of immediately available funds to an account
specified by the Placement Agent to the Company on or prior to the Closing Date; provided, however, that the portion
of such expense reimbursement specified by the Placement Agent to the Company to be applied toward the legal fees and expenses
incurred by the Placement Agent in connection with the Transactions shall be paid directly to the Placement Agent’s counsel
by wire transfer of immediately available funds to an account specified by the Placement Agent or its counsel to the Company on
or prior to the Closing Date.

 

(g)
Corporate Proceedings. All corporate proceedings and other legal matters incident to the authorization, form and validity
of the Transaction Documents and Securities and all other legal matters relating to the offering, issuance and sale, as applicable,
of the Securities and the other Transactions shall be reasonably satisfactory in all material respects to the Placement Agent;
and the Company shall have furnished to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Placement Agent, all
documents and information that it may reasonably request to enable them to pass upon such matters, including a Secretary’s
Certificate, if requested.

 

    	11

    	 

    

 

(h)
No Material Adverse Change. The Company has not sustained since the date of the latest audited financial statements incorporated
or deemed incorporated by reference in the Disclosure Package (i) any material loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any strike, job action, slowdown, work stoppage,
labor dispute or court or governmental action, order or decree or (ii) since such date, there shall not have been any change in
the common stock, short-term debt or long-term debt of the Company or any Material Adverse Change, the effect of which, in any
such case set forth in clause (i) or (ii), is, in the judgment of the Placement Agent, so material and adverse as to make it impracticable
or inadvisable to proceed with the Placement or the delivery of the Securities being delivered on the Closing Date on the terms
and in the manner contemplated in this Agreement and the Securities Purchase Agreement.

 

(i)
No Trading Halt or Disruption. Subsequent to the execution and delivery of this Agreement, there shall not have occurred
any of the following: (i) trading in securities generally on the New York Stock Exchange, the NYSE American, The Nasdaq Stock
Market or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter
market, shall have been suspended or the settlement of such trading generally shall have been materially disrupted or minimum
prices shall have been established on any such exchange or such market by the Commission, by such exchange or by any other regulatory
body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been declared by Federal or state authorities
of the United States, (iii) the United States shall have become engaged in hostilities, there shall have been a significant escalation
in hostilities involving the United States or there shall have been a declaration of a national emergency or war by the United
States or (iv) there shall have occurred any other calamity or crisis or any change in general domestic or international economic,
political or financial conditions, including without limitation as a result of terrorist activities, or the effect of international
conditions on the financial markets in the United States shall be such, as to make it, in the sole discretion of the Placement
Agent, impracticable or inadvisable to proceed with the Placement or delivery of the Securities being delivered on the Closing
Date on the terms and in the manner contemplated in this Agreement and the Securities Purchase Agreement.

 

(j)
Transaction Documents. Each of the Transaction Documents, other than this Agreement, shall be in form and substance reasonably
satisfactory to the Placement Agent and shall have been duly executed and delivered by the Company and the other parties thereto,
and the Securities shall have been duly executed (as applicable) and delivered by the Company.

 

(k)
Conditions. All conditions to closing set forth in the Securities Purchase Agreement shall be satisfied or, where applicable,
waived.

 

(l)
No Injunction. The issuance and sale of the Preferred Stock and the Warrants to the Purchasers shall not be enjoined (temporarily
or permanently) on the Closing Date.

 

(m)
Additional Documents. On or before the Closing Date, the Placement Agent shall have received such information, documents and
opinions as they may reasonably require in order to evidence the accuracy of any of the representations and warranties, or the
satisfaction of any of the conditions or agreements, herein contained.

 

    	12

    	 

    

 

Section
5. Indemnification.

 

(a)
Indemnification of the Placement Agent. The Company agrees to indemnify and hold harmless the Placement Agent and its affiliates
and their respective officers, directors, managers, members, partners, employees and agents, and any other persons controlling
the Placement Agent or any of its affiliates within the meaning of either Section 15 of the Securities Act or Section 20 of the
Exchange Act (the Placement Agent and each such other person being referred to as an “Indemnified Person”),
to the fullest extent lawful, from and against all claims, liabilities, losses, damages and expenses (or any actions, claims,
suits or proceedings in respect thereof), as incurred (“Losses”) related to or arising out of or in connection
with the Placement Agent’s services hereunder, to which such Indemnified Person may become subject under the Securities
Act, the Exchange Act or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions
where the Securities have been offered or at common law or otherwise (including in settlement of any litigation), insofar as such
Losses (or actions in respect thereof as contemplated below) arises out of or is based upon:

 

(A)
(i) any untrue statement or alleged untrue statement of a material fact contained in the Disclosure Package (or any
amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(ii)
any untrue statement or alleged untrue statement of a material fact contained in any materials or information provided to investors
by, or with the approval in writing of, the Company in connection with the offering of the Securities and the Placement, including
any investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; or

 

(iii)
any breach by the Company of any representation or warranty or failure to comply with any of the covenants and agreements contained
or incorporated by reference in this Agreement; and

 

(B)
the violation by the Company of any applicable laws or regulations of any jurisdiction where the Securities have been offered;
and to reimburse the Indemnified Person for:

 

(i)
all expenses (including, without limitation, reasonable fees and expenses of counsel chosen by the Placement Agent) as such expenses
are incurred by the Placement Agent in connection with investigating, preparing, defending or settling any action or claim for
which indemnification has or is reasonably likely to be sought by the Indemnified Person, whether or not in connection with litigation
in which any Indemnified Person is a named party; and

 

(ii)
any other Losses incurred by the Placement Agent.

 

    	13

    	 

    

 

The
indemnity agreement set forth in this Section 5(a) shall be in addition to any liabilities that the Company may otherwise
have, including without limitation under Section 19 of the Engagement Letter, dated October 1, 2018 (as the same may be amended
from time to time, the “Engagement Letter”), between the Placement Agent and the Company, a copy of which is
attached as Exhibit G hereto.

 

(b)
Notifications and Other Indemnification Procedures. Promptly after receipt by an Indemnified Person under this Section
5 of notice of the commencement of any action, such Indemnified Person will, if a claim in respect thereof is to be made against
the Company under this Section 5, notify the Company in writing of the commencement thereof, but the omission so to notify
the Company will not relieve it from any liability which it may have to any Indemnified Person for indemnification, except to
the extent that the Company shall have been materially prejudiced by such failure. In case any such action is brought against
any Indemnified Person and such Indemnified Person seeks or intends to seek indemnity from an Company, the Company will be entitled
to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by
written notice delivered to the Indemnified Person promptly after receiving the aforesaid notice from such Indemnified Person,
to assume the defense thereof with counsel reasonably satisfactory to such Indemnified Person; provided, however, if the defendants
in any such action include both the Indemnified Person and the Company and the Indemnified Person shall have reasonably concluded
that a conflict may arise between the positions of the Company and the Indemnified Person in conducting the defense of any such
action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional
to those available to the Company, the Indemnified Person or parties shall have the right to select separate counsel to assume
such legal defenses and to otherwise participate in the defense of such action on behalf of such Indemnified Person or parties.
Upon receipt of notice from the Company to such Indemnified Person of the Company’s election so to assume the defense of
such action and approval by the Indemnified Person of counsel, the Company will not be liable to such Indemnified Person under
this Section 5 for any legal or other expenses subsequently incurred by such Indemnified Person in connection with the
defense thereof unless (i) the Indemnified Person shall have employed separate counsel in accordance with the proviso to the preceding
sentence (it being understood, however, that the Company shall not be liable for the expenses of more than one separate counsel
(together with local counsel), approved by the Company, representing the indemnified parties who are parties to such action) or
(ii) the Company shall not have employed counsel satisfactory to the Indemnified Person to represent the Indemnified Person within
a reasonable time after notice of commencement of the action, in each of which cases the fees and expenses of counsel shall be
at the expense of the Company.

 

(c)
Settlements. The Company under this Section 5 shall not be liable for any settlement of any proceeding effected
without its written consent, which consent shall not be unreasonably withheld, but if settled with such consent or if there be
a final judgment for the plaintiff, the Company agrees to indemnify the Indemnified Person against any Losses by reason of such
settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested the
Company to reimburse the Indemnified Person for fees and expenses of counsel as contemplated by Section 5(b) hereof, the
Company agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement
is entered into more than 30 days after receipt by the Company of the aforesaid request and (ii) the Company shall not have reimbursed
the Indemnified Person in accordance with such request prior to the date of such settlement. The Company shall not, without the
prior written consent of the Indemnified Person, effect any settlement, compromise or consent to the entry of judgment in any
pending or threatened action, suit or proceeding in respect of which any Indemnified Person is or could have been a party and
indemnity was or could have been sought hereunder by such Indemnified Person, unless such settlement, compromise or consent includes
(i) an unconditional release of such Indemnified Person from all liability on claims that are the subject matter of such action,
suit or proceeding and (ii) does not include a statement as to, or an admission of, fault, culpability or a failure to act, by
or on behalf of any Indemnified Person.

 

    	14

    	 

    

 

Section
6. Contribution. If the indemnification provided for in Section 5 is for any reason held to be unavailable to or otherwise
insufficient to hold harmless an Indemnified Person in respect of any Losses referred to therein, then the Company shall contribute
to the aggregate amount paid or payable by such Indemnified Person, as incurred, as a result of any Losses referred to therein
(i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Placement
Agent, on the other hand, from the Placement pursuant to this Agreement or (ii) if the allocation provided by clause (i) above
is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause (i) above but also the relative fault of the Company, on the one hand, and the Placement Agent, on the other hand, in
connection with the statements or omissions which resulted in such Losses, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Placement Agent, on the other hand, in connection with
the Placement pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from
the Placement pursuant to this Agreement (before deducting expenses) received by the Company, and the fee received by the Placement
Agent in connection with the Placement. The relative fault of the Company, on the one hand, and the Placement Agent, on the other
hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand,
or the Placement Agent, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission. Notwithstanding the provisions of this Section 6, the aggregate contribution
of all Indemnified Persons to all Losses shall not exceed the amount of the fees actually received by the Placement Agent pursuant
to this Agreement with respect to the services rendered pursuant to this Agreement.

 

The
Company agrees to reimburse the Indemnified Persons for all expenses (including, without limitation, reasonable fees and expenses
of counsel) as they are incurred in connection with investigating, preparing, defending or settling any action or claim for which
contribution has been sought by the Indemnified Person, whether or not in connection with litigation in which any Indemnified
Person is a named party.

 

The
provisions set forth in Section 5(c) with respect to notice of commencement of any action shall apply if a claim for contribution
is to be made under this Section 6; provided, however, that no additional notice shall be required with respect
to any action for which notice has been given under Section 5(b) for purposes of indemnification.

 

 

    	15

    	 

    

 

The
Company and the Placement Agent agree that it would not be just and equitable if contribution pursuant to this Section 6
were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to in this Section 6.

 

No
person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 6, each
officer and employee of the Placement Agent and each person, if any, who controls the Placement Agent within the meaning of the
Securities Act and the Exchange Act shall have the same rights to contribution as the Placement Agent.

 

Section
7. Effectiveness of this Agreement; Termination; and Survival.

 

(a)
This Agreement shall become effective upon signing by the parties hereto.

 

(b)
The Placement Agent may resign and terminate this Agreement at any time and the Company may terminate the Placement Agent’s
services and terminate this Agreement at any time, in each case by giving at least fifteen (15) days’ prior written notice
thereof to the other party. If the Placement Agent resigns because of the failure of any condition specified in Section 4
to be satisfied when and as required (whether or not the Company’s fault directly or indirectly) or the Company terminates
the Placement Agent’s services for any reason, the Placement Agent and its counsel shall be entitled to receive all of the
amounts due pursuant to and in accordance with the Engagement Letter up to, and including, the effective date of such expiration,
termination or resignation, as the case may be.

 

(c)
The respective representations, warranties and other statements of the Company and its officers and the agreements, covenants
and the indemnities set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation
made by or on behalf of the Placement Agent or the Company or any of its or their partners, members, officers, directors, employees,
agents or representatives, or any controlling person of the Placement Agent, as the case may be, and will survive delivery of
and payment for the Securities sold hereunder or any termination of this Agreement (for whatever reason).

 

Section
8. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed
to the parties hereto as follows:

 

If
to the Placement Agent:

 

A.G.P./Alliance
Global Partners

590
Madison Avenue

New
York, NY 10022

Email:
db@allianceg.com

Attention:
David Bocchi

 

with
a copy to:

 

Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

666 Third Avenue

New York, New York 10017

Facsimile: (212) 983-3115

Attention: Anthony J. Marsico, Esq.

 

    	16

    	 

    

 

If
to the Company:

 

Ritter
Pharmaceuticals, Inc.

1880
Century Park East, Suite 1000

Los
Angeles, CA 90067

Facsimile:
(310) 919-1600

Attention:

 

with
a copy to:

Reed
Smith LLP

1901
Avenue of the Stars

Suite
700

Los
Angeles, CA 90067-6708

Facsimile:
(310) 734-5299

Attention:
Michael Sanders, Esq.

 

Any
party hereto may change the address for receipt of communications by giving written notice to the others.

 

Section
9. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the
employees, officers and directors and controlling persons referred to in Section 5 and Section 6, and in each case
their respective successors, and personal representatives, and no other person will have any right or obligation hereunder. The
term “successors” shall not include any Purchaser.

 

Section
10. Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement
shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph
or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such
minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

 

Section
11. Governing Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the
State of New York. Any legal suit, action or proceeding arising out of or based upon this Agreement or the Transactions (“Related
Proceedings”) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan
in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of
New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction
(except for proceedings instituted in regard to the enforcement of a judgment of any such court (a “Related Judgment”),
as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.

 

    	17

    	 

    

 

Section
12. General Provisions. This Agreement and the Engagement Letter constitute the entire agreement of the parties to this Agreement
with respect to the subject matter hereof and thereof and supersedes all prior written or oral and all contemporaneous oral agreements,
understandings and negotiations with respect to the subject matter hereof and thereof, except for those certain terms incorporated
into this Agreement from the Securities Purchase Agreement. Nothing in this Agreement should be read to limit or otherwise modify
the terms and other provisions of the Engagement Letter, provided that, in the event any terms of the Engagement Letter or Indemnification
Letter are inconsistent with or contradict any terms of this Agreement, this Agreement shall govern. This Agreement may be executed
in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto
were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and
no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.
The failure by any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising
such right or remedy, shall not operate as a waiver thereof. The Section headings herein are for the convenience of the parties
only and shall not affect the construction or interpretation of this Agreement.

 

Each
of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 5
and the contribution provisions of Section 6, and is fully informed regarding said provisions. Each of the parties hereto
further acknowledges that the provisions of Sections 5 and 6 hereto fairly allocate the risks in light of the ability
of the parties to investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made
in the Disclosure Package (and any amendments and supplements thereto), as required by the Securities Act, the Exchange Act and
any other applicable law.

 

    	18

    	 

    

 

If
the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies
hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its
terms.

 

	 	Very truly yours,
	 	 
	 	RITTER PHARMACEUTICALS CORPORATION
	 	 
	 	By:	                               
	 	Name:	 
	 	Title:	 

 

The
foregoing Placement Agency

Agreement is hereby confirmed

and accepted by the Placement Agent

in New York, New York as of the

date first above written.

 

A.G.P./ALLIANCE
GLOBAL PARTNERS

 

	By:
    	 	 
	Name:
    	David
    Bocchi	 
	Title:	Head
    of Investment Banking	 

 

    	 

    	 

    

 

EXHIBIT
A-1

 

FORM
OF SERIES B CERTIFICATE OF DESIGNATIONS

 

    	 	Exhibit A-1	 

     

    
 

EXHIBIT
A-2

 

FORM
OF SERIES C CERTIFICATE OF DESIGNATIONS

 

    	 	Exhibit A-2	 

     

    
 

EXHIBIT
B

 

FORM
OF WARRANTS

 

    	 	Exhibit B	 

     

    
 

EXHIBIT
C

 

FORM
OF SECURITIES PURCHASE AGREEMENT

 

    	 	Exhibit C	 

     

    
 

EXHIBIT
D

 

FORM
OF REGISTRATION RIGHTS AGREEMENT

 

    	 	Exhibit D	 

     

    
 

EXHIBIT
E

 

FORM
OF ESCROW AGREEMENT

 

    	 	Exhibit E	 

     

    
 

EXHIBIT
F

 

OPINION
OF COMPANY COUNSEL

 

References
to the Disclosure Package in this Exhibit F include any supplements thereto at the Closing Date.

 

1.
The execution, delivery and performance of each of the Engagement Letter, the Placement Agency Agreement and the Escrow Agreement
by the Company have been duly authorized by all necessary corporate action of the Company and each has been duly executed and
delivered by the Company.

 

2.
Each of the Engagement Letter, the Placement Agency Agreement and the Escrow Agreement constitutes a valid and binding obligation
of the Company and each is enforceable against the Company in accordance with its terms.

 

3.
The execution, delivery and performance of each of the Engagement Letter, the Placement Agency Agreement and the Escrow Agreement
by the Company, in each case will not, with or without the giving of notice or the lapse of time or both, (a) result in any breach
of or constitute a default under the Certificate of Incorporation or Bylaws, (b) contravene any provision of New York law, federal
law or the DGCL, or any rule or regulation thereunder, in each case that, in our experience, is typically applicable to transactions
of the nature contemplated by the Engagement Letter, the Placement Agency Agreement and the Escrow Agreement and is applicable
to the Company, (c) to our knowledge, result in any breach of or constitute a default under any currently effective decree, judgment
or order currently applicable to the Company, or (d) result in any breach of or constitute a default under any Material Agreement.

 

4.
No consent, approval, authorization or other order of, or registration or filing with, any United States federal, New York or
Delaware court or other governmental or regulatory authority or agency that, in our experience, is normally applicable to transactions
of the type contemplated by the Engagement Letter, the Placement Agency Agreement and the Escrow Agreement is required for the
consummation of the transactions contemplated by the Engagement Letter, the Placement Agency Agreement and the Escrow Agreement,
except for the filing of a Form D under the Securities Act, and such consents, approvals, authorizations, orders and registrations
or filings as may be required under applicable state securities laws, as to which we express no opinion, and from the NASDAQ Capital
Market (which has been obtained).

 

5.
We confirm to you that we are not representing the Company in any pending litigation in which the Company is a named defendant
that challenges the validity or enforceability of any of the Engagement Letter, the Placement Agency Agreement or the Escrow Agreement,
or seeks to enjoin the performance of or the consummation of any of the transactions contemplated by any of the Engagement Letter,
the Placement Agency Agreement and the Escrow Agreement.

 

    	 	Exhibit F	 

     

    
 

EXHIBIT
G

 

ENGAGEMENT
LETTER

 

    	 	Exhibit G

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]